Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 7(312): 312ra176, 2015 Nov 04.
Article in English | MEDLINE | ID: mdl-26537256

ABSTRACT

Amplification of the MYCN oncogene predicts treatment resistance in childhood neuroblastoma. We used a MYC target gene signature that predicts poor neuroblastoma prognosis to identify the histone chaperone FACT (facilitates chromatin transcription) as a crucial mediator of the MYC signal and a therapeutic target in the disease. FACT and MYCN expression created a forward feedback loop in neuroblastoma cells that was essential for maintaining mutual high expression. FACT inhibition by the small-molecule curaxin compound CBL0137 markedly reduced tumor initiation and progression in vivo. CBL0137 exhibited strong synergy with standard chemotherapy by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells and suggesting a treatment strategy for MYCN-driven neuroblastoma.


Subject(s)
Antineoplastic Agents/pharmacology , Carbazoles/pharmacology , DNA-Binding Proteins/antagonists & inhibitors , High Mobility Group Proteins/antagonists & inhibitors , Nervous System Neoplasms/drug therapy , Nervous System Neoplasms/metabolism , Neuroblastoma/drug therapy , Neuroblastoma/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Transcriptional Elongation Factors/antagonists & inhibitors , Antineoplastic Agents/therapeutic use , Carbazoles/therapeutic use , DNA Repair/drug effects , DNA-Binding Proteins/metabolism , High Mobility Group Proteins/metabolism , Humans , Molecular Targeted Therapy , Signal Transduction/drug effects , Transcriptional Elongation Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...